1. Alonso, J., Angermeyer, M. C., Bernert, S., et al., “12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project,” Acta Psychiatr. Scand., 109, No. 1420, Supplement, 28–37 (2004).
2. Anderson, I. M., “SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability,” Depress. Anxiety, 7, No. 1, 11–17 (1998).
3. Andreescu, C., Lenze, E. J., Dew, M., et al., “Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study,” Br. J. Psychiatry, 190, 344–349 (2007).
4. Arroll, B., Macgillivray, S., Ogston, S., et al., “Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis,” Ann. Fam. Med., 3, 449–456 (2005).
5. Avgustinovich, D. F., Alekseenko, O. V., Bakshtanovskaya, I. V., et al., “Dynamic changes in serotoninergic and dopaminergic activity in the brain during the development of anxious depression: an experimental study,” Usp. Fiziol. Nauk., 35, 19–40 (2004a).